Application 215465
- Type
- ANDA
- Sponsor
- KNACK
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | LEVETIRACETAM | LEVETIRACETAM | INJECTABLE;INTRAVENOUS | 500MG/5ML (100MG/ML) | No | No |
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A215465-001 | LEVETIRACETAM | LEVETIRACETAM | 500MG/5ML (100MG/ML) | INJECTABLE / INTRAVENOUS | 2025-12-02 |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-09-14 22:38:34 | 2026-08 | A215465-001 | LEVETIRACETAM | 500MG/5ML (100MG/ML) | INJECTABLE / INTRAVENOUS | 2025-12-02 | 84e616aacf4f… | ||
| 2026-08-18 06:07:40 | 2026-07 | A215465-001 | LEVETIRACETAM | 500MG/5ML (100MG/ML) | INJECTABLE / INTRAVENOUS | 2025-12-02 | caaa826d4ba7… | ||
| 2026-02-19 14:30 UTC | 2026-02 | A215465-001 | LEVETIRACETAM | 500MG/5ML (100MG/ML) | INJECTABLE / INTRAVENOUS | AP | 2025-12-02 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A215465-001 | LEVETIRACETAM | 500MG/5ML (100MG/ML) | INJECTABLE / INTRAVENOUS | AP | 2025-12-02 | 31067a03dcf5… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A215465-001 | LEVETIRACETAM | 500MG/5ML (100MG/ML) | INJECTABLE / INTRAVENOUS | 2025-12-02 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-02-19 14:30 UTC | 2026-02 | A215465-001 | AP | 1 | 011fe1cb6892… |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | A215465-001 | AP | 1 | 31067a03dcf5… |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Levetiracetam | LEVETIRACETAM | Aryeh Pharma corp | 4f8ffd81-f814-f288-e063-6394a90a5eb5 | 2026-04-16 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | Safecor Health LLC | e72a7410-13fd-40e4-befb-052d0455e038 | 2026-04-09 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | Bryant Ranch Prepack | 7696961e-dfff-422a-b72f-e31ceeac10af | 2026-04-08 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | Bryant Ranch Prepack | 24f815ef-58e6-42b9-8137-adcd6c382aa6 | 2026-04-02 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| LEVETIRACETAM | LEVETIRACETAM | Torrent Pharmaceuticals Limited | 7cb669d7-d1aa-43b3-a322-0a2eaa13c656 | 2026-04-02 | Warnings, Adverse reactions | LEVETIRACETAM LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | Bryant Ranch Prepack | 9e3171c9-70e2-4725-8aca-c7f83773940d | 2026-04-02 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | BluePoint Laboratories | 402b488c-1733-4bf7-a7a8-b60805b022c9 | 2026-03-30 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | Sun Pharmaceutical Industries, Inc. | bf412e94-ca36-4da9-83d7-fb0f1323cf21 | 2026-03-23 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | A-S Medication Solutions | 02e237ff-a3e0-40fe-a3d0-9d8802855c71 | 2026-03-23 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| LEVETIRACETAM solution | LEVETIRACETAM | Chartwell RX, LLC | 61eb57a9-5df2-4426-9f0c-a75e2f356b11 | 2026-03-13 | Warnings, Adverse reactions | LEVETIRACETAM |
| LEVETIRACETAM | LEVETIRACETAM | DIRECT RX | c3b62114-a590-f4db-e053-2995a90a9d30 | 2026-03-05 | Warnings, Adverse reactions | LEVETIRACETAM LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | Fresenius Kabi USA, LLC | da858849-1d18-4d38-b53d-d4dd1cd8fabc | 2026-02-05 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | A-S Medication Solutions | 30f43d3b-c944-4f25-b5d3-009294944962 | 2026-02-02 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Keppra | LEVETIRACETAM | UCB, Inc. | 3ca9df05-a506-4ec8-a4fe-320f1219ab21 | 2026-01-28 | Warnings, Adverse reactions | LEVETIRACETAM |
| LEVETIRACETAM Extended-release | LEVETIRACETAM | Omnivium Pharmaceuticals LLC | 1a31134d-6b63-4d14-8445-0ed132e6c88d | 2026-01-16 | Warnings, Adverse reactions | LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | Northwind Health Company, LLC | fc4c72e2-9cba-88d9-e053-6394a90a0426 | 2026-01-01 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | A-S Medication Solutions | deca634a-651e-4c70-9fc3-b0087b537b0a | 2025-12-30 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | A-S Medication Solutions | c3daf220-9741-41c4-b89d-e06cee36dac6 | 2025-12-30 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| Levetiracetam | LEVETIRACETAM | Cranbury Pharmaceuticals, LLC | b1e988f7-8bbe-4ef4-8b0a-b2a8af8a482b | 2025-12-28 | Warnings, Adverse reactions | Levetiracetam LEVETIRACETAM |
| LEVETIRACETAM | LEVETIRACETAM | Method Pharmaceuticals, LLC | 47cfe577-b4cb-d35e-e063-6394a90ad8c4 | 2025-12-16 | Warnings, Adverse reactions | LEVETIRACETAM LEVETIRACETAM |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.